This study aims to explore how painful and non-painful stimuli are processed in people with and without nerve pain with chronic SCI. We are recruiting individuals with spinal cord injury at T11 and above, with or without neuropathic pain in the leg, and who are able to stand with or without an assistive device. Study participation involves 3 in-person visits, each of which will last 2-3 hours. Compensation and mileage reimbursement are available for all study visits.

DROP-FPF is a clinical study that will assess whether an investigational medication called nerandomilast can reduce the risk of interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) getting worse over time. By learning more about people with early lung abnormalities, it may inform researchers how to reduce the risk of developing progressive pulmonary fibrosis.

This study aims to evaluate real-world effectiveness of pacritinib through a site-based retrospective chart review of medical records of adult patients with myelofibrosis treated with pacritinib in routine clinical settings with platelet count ≥50 x 10^9/L at the time of treatment initiation. Treatment effectiveness will be based on spleen size and symptom burden, hematological parameters, progression to leukemia, survival, pacritinib treatment patterns, patient demographic and clinical characteristics, and allogenic-hematopoietic stem cell transplant (allo-HSCT)-related outcomes. Data will be collected from medical charts of patients with pacritinib initiation between 01 June 2022 and 31 December 2025 with an end of study observation on 30 June 2026.

This research study explores the experiences of adults with spinal cord injury (SCI) when managing menstrual hygiene. Recommendations for occupational therapy (OT) interventions to support participation are also included. Information will be gathered from each participant through a survey and a virtual interview. This study aims to answer the following questions: How do adults living with SCI manage menstrual hygiene? What challenges do they face? What role can OT play in supporting them?

This study aims to improve the early identification of depression and substance use concerns during pregnancy and after childbirth by developing an artificial intelligence (AI) tool that uses information already collected in electronic health records. The goal is to help healthcare providers identify individuals who may be at risk for mental health or substance use problems earlier, allowing for timely support and treatment. Researchers will also work closely with patients, healthcare providers, and community partners to ensure the AI tool is trustworthy, easy to use, fair, and able to fit into routine healthcare settings.
The study includes two components. First, researchers will use existing electronic health record data from pregnant patients to develop and test an AI model that can predict the likelihood of depression or substance use concerns. Second, pregnant or postpartum individuals and obstetric healthcare providers will participate in a one-time virtual interview/focus group to share their perspectives on the use of AI in maternal healthcare. Feedback from these interviews/focus groups will help refine the AI tool and support its future implementation in clinical care.

This study is for patients that have been diagnosed with relapsed and refractory multiple myeloma (RRMM). This study is testing and investigational drug called KTX-1001. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of this study is to test the safety and tolerability of KTX-1001 and to find out how it is processed by the body. The drug is given to participants by mouth. Participants in this study can expect to be in this study until disease progression, unacceptable toxicity, or withdrawal from the study. The total duration of the study may be approximately 4 years.

This study is recruiting pediatric patients who have been diagnosed with Favorable Histology Wilms Tumor (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. The goal of the study to improve outcomes within cohorts of FHWT patients with current long-term EFS rates at or below 80% and maintain outcomes despite therapy reduction within cohorts of FHWT patients with current long-term EFS rates at or above 84%. Common side effects of treatment in regards to this study include nausea, vomiting, hair loss, and fatigue (tiredness). Participants will receive the medications through an IV in their arm and orally. Study participation is expected to be approximately 5 years.

The 16-week main phase of the study is designed to assess the efficacy and safety of the once daily pitolisant, administered orally upon wakening, in comparison to a placebo. This study includes overnight sleep studies. The effects of HBS-301 on excessive daytime sleepiness, fatigue, and cataplexy (NT1 population only) will be examined.

After the main phase period, there is an option to be in the second part of the study, which will span 1 year. During this period, subjects will receive open label of the active drug, HBS-301.

This study aims to pilot test a virtual mindfulness meditation program for pulmonary hypertension (PH) in preparation for larger testing. Individuals living with PH will be invited to learn mindfulness practices via videos and the MMPH app for 8 weeks.

They will provide feedback via surveys at four time points: before and after the intervention (PAHSS, EmPHass-10, PHQ-8, PCL-5, CAMS-R), and again 1 month and 2 months after. They will be asked to wear a wrist actigraphy device before and after the intervention.

Participants will provide their feedback via an interview about their experience after the intervention is complete.

This study is evaluating a program designed to support adults recovering from a traumatic injury, such as a motor vehicle crash, fall, or other serious injury. Recovery after an injury can be challenging, particularly for people who are experiencing emotional distress as well as difficulties with needs such as housing, food, transportation, or finances. The program, called TRRP+, combines mental health support with assistance from a Community Health Worker who can help participants identify needs, connect with available resources, and navigate services during their recovery. The study will include approximately 100 adults who have experienced a traumatic injury and report emotional distress and at least one unmet social need.
Researchers will examine whether TRRP+ is practical and helpful for patients and will gather feedback from participants, Community Health Workers, and trauma center staff about their experiences with the program. The information learned from this study will help researchers understand how programs like TRRP+ can better support patients' emotional, social, and practical needs as they recover from a traumatic injury.